The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer.
M. Basik
No relevant relationships to disclose
D. Keilty
No relevant relationships to disclose
O. Aleynikova
No relevant relationships to disclose
D. Tu
No relevant relationships to disclose
X. Li
No relevant relationships to disclose
L. E. Shepherd
No relevant relationships to disclose
V. Bramwell
No relevant relationships to disclose